Aurobindo Pharma announced Friday that it has established a manufacturing presence in Indonesia through the creation of two new corporate entities [1].
This expansion allows the company to localize production in Southeast Asia, reducing reliance on exports and potentially lowering costs for regional distribution. By establishing a physical footprint in Indonesia, the firm can better navigate local regulatory requirements and meet the growing demand for affordable medicine in the region.
The company created a wholly owned stepdown subsidiary known as PT Aurogen Pharma Indonesia [1]. Additionally, the firm incorporated PT Auro Pharm Indonesia to specifically handle manufacturing operations [1].
These organizational steps were finalized around July 9 [1]. The strategic move signals a shift toward diversifying the company's global production hubs, moving beyond its primary bases to capture more of the Indonesian market.
"Aurobindo Pharma on Friday (July 10, 2026) announced the incorporation..." the company said in a statement reported by The Hindu [1].
The establishment of these two entities provides the legal and operational framework necessary to build facilities and hire local staff. This infrastructure is designed to support the long-term goal of scaling pharmaceutical output within the country [1].
“Aurobindo Pharma has set up a wholly owned stepdown subsidiary, PT Aurogen Pharma Indonesia.”
Aurobindo Pharma's entry into Indonesia represents a strategic pivot toward localized manufacturing in emerging markets. By establishing both a subsidiary and a dedicated manufacturing arm, the company is positioning itself to bypass import tariffs and supply chain disruptions that often affect cross-border pharmaceutical trade in Southeast Asia.
